Abstract：Objective: To study the efficacy of Bisoprolol Combined with Fordostein in the treatment of COPD and its effect on serum human clara cell protein (CC16), soluble E-selectin (sE-SLT) and serum amyloid A (SAA). Methods: 81 patients of COPD who received therapy from March 2017 to March 2018 in our hospital were selected as research objects. According to random number table,those patients were divided into observation group (41 cases) and control group (39 cases) by random number table, Routine treatment was given in both groups,The patients in the observation group were treated with bisoprolol combined with fordostein, fordostein 0.4g, three times a day.Patients in the control group were treated with Bisoprolol. The course of treatment was 3 months in both groups. Then Serum CC16, sE-SLT, SAA, efficacy and adverse reactions were compared between the two groups. Results: The total effective rate of the observation group was 92.85% (3/42). The total effective rate of the control group was 66.66% (13/39). The difference has statistical significance(P＜0.05). CC16 in the observation group and the control group were (0.50±0.02)and (0.85±0.05), respectively. sE-SLT in the observation group and the control group were(17.67±2.78)and(22.08±4.54), respectively. SAA in the observation group and the control group were(34.84±2.37)and(46.09±4.46), respectively, The difference has statistical significance(P＜0.05). During the treatment, there were 1 case of wheezing, 1 case of dizziness and 1 case of fatigue in the observation group.There were 2 cases of wheezing, 3 cases of dizziness and 2 cases of fatigue in the control group. The total incidence of adverse reactions in the two groups was 7.14% (3/42) and 17.94% (7/39), respectively. There was no significant difference between the two groups(P＞0.05). Conclusion: Bisoprolol combined with Fordostein is effective in the treatment of COPD. It can improve clinical symptoms, cardiopulmonary function, bronchiectasis, reduce serum levels of CC16, sE-SLT and SAA, with fewer adverse reactions, and is safe and reliable.
刘魏, 张毅. 比索洛尔联合福多司坦治疗COPD的疗效及对血清CC16 sE-SLT SAA的影响[J]. 河北医学, 2019, 25(10): 1624-1626.
LIU Wei, ZHANG Yi. Efficacy of Bisoprolol Combined with Fordostein in the Treatment of COPD and the Effect on Serum CC16 sE-SLT and SAA. HeBei Med, 2019, 25(10): 1624-1626.
[1] Kourlaba G, Hillas G, Vassilakopoulos T, et al. The economic burden of chronic obstructive pulmonary disease in greece[J]. Applied Health Economics and Health Policy, 2019, 17(1):111~121. [2] Fang Y, Wang H, Wang L, et al. Feature-maximum-dependency-based fusion diagnosis method for COPD[J]. Multimedia Tools and Applications, 2019,28(1):1~18. [3] Moon J Y, Sin D D. Inhaled corticosteroids and fractures in chronic obstructive pulmonary disease: current understanding and recommendations[J]. Current opinion in pulmonary medicine, 2019, 25(2):165~166. [4] 何芳,刘美成,秦勤.长期使用他汀类药物降低COPD患者死亡风险及肺动脉压的Meta分析[J].药物流行病学杂志,2018,27(12):785~792. [5] 杨莉平,欧阳瑶.DCs、Th1及Th2细胞在COPD免疫机制中的作用研究[J].医学综述,2018,24(22):4427~4432. [6] 谢小晨,王娜娜,陈亮,等.福多司坦联合噻托溴铵治疗稳定期慢性阻塞性肺疾病临床疗效观察[J].中国实用内科杂志,2017,37(8):749~751.
2019, Vol. 25 
冀公网安备13080202000677号